A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

Ketamine is only approved by the FDA as an anesthetic, but there is growing interest in using ketamine products to treat ...

The company is developing psychedelics for depression, and hopes to go public within a year of its next published results, per documents seen by BI.

Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of ...

The trailer for Season 27 of South Park has been released, and the animated satirical sitcom appears to have a new target: Elon Musk. Newsweek has reached out to X outside of normal working hours via ...

Discover how the brain's most abundant neurotransmitter, glutamate, is revolutionizing psychiatry and offering new hope for ...

The trailer for the 27th series of South Park has dropped and it appears to include a few swipes at Elon Musk, in regards to ...

Tasman Therapeutics, Inc. (Tasman) has announced plans to raise $175 million in Series A funding to support the late-stage clinical development and eventual commercialization of R-107. This innovative ...

As mental health professionals increasingly adopt ketamine in clinical settings, understanding its benefits and risks is critical.

It’s a strong tranquilliser that’s historically been used as an anaesthetic in hospitals and vets, but recent data suggests that ketamine has become a popular party drug with Gen Z. Latest government ...